arrow
X

Xi-Fei Jiang

fudan university
H指数:19
被引数:1,131

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting HMGB2 acts as dual immunomodulator by bolstering CD8+ T cell function and inhibiting tumor growth in hepatocellular carcinoma

靶向HMGB2通过增强CD8+ T细胞功能并抑制肿瘤生长,在肝细胞癌中充当双重免疫调节剂。

2025-05-020
OA
Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial

Efgartigimod治疗胸腺瘤相关重症肌无力的围手术期安全性与有效性:一项前瞻性、多中心、II期临床研究

2025-05-020
PRE
Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming

癌症相关成纤维细胞通过CD36-mediated脂肪酸代谢重编程促进肝细胞癌复发和转移

2024-02-0112
PRE
Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma

多组学分析揭示了代谢亚型,并确定了二酰甘油激酶 α (DGKA) 作为肝内胆管癌的潜在治疗靶点

2023-12-242
OAAI
Single-cell and spatial architecture of primary liver cancer
2023-11-2011
OAAI
Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation

预测肝移植后肝癌复发的深度病理学评分的建立

2023-04-0822
OAAI
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

使用toripalimab,lenvatinib和TACE联合治疗最初无法切除的肝细胞癌的转化治疗: 真实世界研究

2022-09-2046
OAAI
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack
2022-02-0763
PRE
Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: a multicenter retrospective study
2019-12-127
OAAI